
Avillion hires chief business officer
pharmafile | September 25, 2014 | Appointment | Manufacturing and Production, Medical Communications, Research and Development, Sales and Marketing | Avillion, Jarrod Longcor, melinta, rib-x
London-based drug development firm Avillion has confirmed the appointment of Jarrod Longcor as its chief business officer.
Longcor joins as a member of its executive team and will be responsible for negotiating and executing strategic alliances and financial investments, as well as providing management and leadership to the organisation.
Longcor takes over 18 years of pharma and biotech experience to the firm and was previously the vice president of corporate development for Rib-X Pharmaceuticals (now Melinta Therapeutics).
Prior to Rib-X he held senior positions in several small to mid-sized biotech companies, where he was responsible for business development and strategic planning.
Allison Jeynes-Ellis, chief executive of Avillion, says: “It is a great pleasure to welcome Jarrod to our management team at Avillion. He brings valuable corporate development skills, experience and contacts from across the pharmaceutical industry.”






